• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Valneva SE

    6/29/22 5:09:13 PM ET
    $VALN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VALN alert in real time by email
    SC 13G 1 sch13g_valneva1x.htm SC 13G VALNEVA Document

     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549


    SCHEDULE 13G
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. _)*

    VALNEVA SE
    (Name of Issuer)


    Ordinary shares, nominal value €0.15 per share
    (Title of Class of Securities)


    92025Y103 (American Depositary Shares, each representing two ordinary shares)
    (CUSIP Number)

    June 22, 2022
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule
    is filed:


    |_| Rule 13d-1(b)
    |X| Rule 13d-1(c)
    |_| Rule 13d-1(d)


    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.


    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     
     

     

    Page 1 of 6

    CUSIP No. 92025Y103



    1.Names of Reporting Persons. PFIZER INC. 13-5315170
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☐
    (b) ☐
    3.SEC Use Only
    4.Citizenship or Place of Organization: Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON WITH:
    5.Sole Voting Power: 9,549,761 ordinary shares, nominal value €0.15 per share ("Ordinary Shares")
    6.Shared Voting Power: -0-
    7.
    Sole Dispositive Power: 9,549,761 Ordinary Shares
    8.Shared Dispositive Power: -0-
    9.
    Aggregate Amount Beneficially Owned by Reporting Person: 9,549,761 Ordinary Shares are beneficially owned by Pfizer Inc.
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares
    (See Instructions) ☐
    11.
    Percent of Class Represented by Amount in Row (9): 8.1%(1)
    12.Type of Reporting Person (See Instructions): CO
     
     
    (1)  Based on 117,351,857 shares of Ordinary Shares outstanding, consisting of 9,549,761 shares of Ordinary Shares issued to the Reporting Person and 107,802,096 Ordinary Shares outstanding as of March 31, 2022 reported in the issuer’s Unaudited Consolidated Interim financial statements as at March 31, 2022 filed on Form 6-K with the Securities and Exchange Commission on May 5, 2022.

    Page 2 of 6


    CUSIP No. 92025Y103



    ITEM 1.
    (A) NAME OF ISSUER:
    Valneva SE

    (B) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICE:

    6 rue Alain Bombard
    44800 Saint-Herblain, France

    ITEM 2.
    (A) NAME OF PERSONS FILING:
    Pfizer Inc.

    (B) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR IF NONE, RESIDENCE:
    235 E. 42nd Street,
    New York, NY 10017

    (C) CITIZENSHIP:
    Delaware, U.S.A.

    (D) TITLE OF CLASS OF SECURITIES:
    Ordinary Shares

    (E) CUSIP NUMBER:
    92025Y103

    ITEM 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: Not applicable.
    (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78os).
    (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

    (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).
    (f ) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
    (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
    Page 3 of 6


    CUSIP No. 92025Y103


    (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
    (j) ☐ A non-US institution, in accordance with §240.13d-1(b)(1)(ii)(J);
    (k) ☐ Group, in accordance with §230.405 240.13d-1(b)(1)(ii)(K).


    If filing as a non-US institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: Not applicable.  

    ITEM 4. OWNERSHIP.
    The information requested in this item is incorporated herein by reference to the cover page to this Schedule 13G.

    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
    Not applicable.  

    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
    Not applicable.  

    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
    Not applicable.  

    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
    Not applicable.  

    ITEM 9. NOTICE OF DISSOLUTION OF GROUP
    Not applicable.  
    Page 4 of 6


    CUSIP No. 92025Y103

    ITEM 10. CERTIFICATION

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     
     



    Page 5 of 6


    CUSIP No. 92025Y103


     Signature
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: June 29, 2022

    PFIZER INC.

    By: /s/ Susan Grant
    Name: Susan Grant
    Title: Assistant Secretary
     
    Page 6 of 6

    Get the next $VALN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VALN

    DatePrice TargetRatingAnalyst
    8/3/2022$34.00Buy
    H.C. Wainwright
    More analyst ratings

    $VALN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly

      Saint Herblain (France), May, 07 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) has started a review of Valneva's single-dose live attenuated chikungunya vaccine IXCHIQ® based on reports of serious adverse events (SAEs) in elderly people. As a temporary measure, while this review is ongoing, EMA has suspended the use of the vaccine for individuals over 65 years old. EMA has maintained current recommendations for IXCHIQ® for people from 12 to 64 years of age. The decision was taken following a plenary meeting of the Pharmacovigilance Risk Assessment Committee (PRAC) on May 5, 2025 and is based on reports of 17

      5/7/25 11:45:00 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates

      Total revenues of €49.2 million compared to €32.8 million in the first quarter of 2024Cash and cash equivalents of €153.0 million at end of March 2025Further clinical and regulatory progress2025 financial outlook confirmed Saint-Herblain (France), May 7, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today reported its financial results for the first quarter ending March 31, 2025, provided key corporate updates and confirmed its 2025 financial guidance. The condensed consolidated interim financial results are available on the Company's website (Financial Reports – Valneva). Valneva will provide a live webcast of its first quarter 2025 results conference call begi

      5/7/25 1:00:00 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities

      Saint Herblain (France), April 26, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that France's national public health agency, the Haute Autorité de Santé (HAS), has updated its recommendation for use of Valneva's single-dose chikungunya vaccine IXCHIQ® for the prevention of disease caused by the chikungunya virus (CHIKV) following reports of serious adverse events (SAEs) in elderly people with comorbidities during the ongoing vaccination campaign in La Reunion and Mayotte. Valneva has been responding to the French government's call for vaccine supply of IXCHIQ® in La Reunion1 as the island is going through a major chikungunya outbreak with ~ 40,000

      4/26/25 1:10:00 PM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VALN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Valneva SE with a new price target

      H.C. Wainwright initiated coverage of Valneva SE with a rating of Buy and set a new price target of $34.00

      8/3/22 7:27:56 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VALN
    SEC Filings

    See more
    • SEC Form 6-K filed by Valneva SE

      6-K - Valneva SE (0001836564) (Filer)

      5/7/25 12:11:21 PM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Valneva SE

      6-K - Valneva SE (0001836564) (Filer)

      4/28/25 7:49:20 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Valneva SE

      6-K - Valneva SE (0001836564) (Filer)

      4/18/25 6:49:09 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VALN
    Financials

    Live finance-specific insights

    See more
    • Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates

      Total revenues of €49.2 million compared to €32.8 million in the first quarter of 2024Cash and cash equivalents of €153.0 million at end of March 2025Further clinical and regulatory progress2025 financial outlook confirmed Saint-Herblain (France), May 7, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today reported its financial results for the first quarter ending March 31, 2025, provided key corporate updates and confirmed its 2025 financial guidance. The condensed consolidated interim financial results are available on the Company's website (Financial Reports – Valneva). Valneva will provide a live webcast of its first quarter 2025 results conference call begi

      5/7/25 1:00:00 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook

      Met 2024 growth targets for product sales (+13% vs 2023) and total revenues (+10% vs 2023)Strong year-end cash position of €168.3 million including sale of Priority Review Voucher1, successful private placement and 67% reduction in operating cash burnSubstantial clinical and regulatory progress in 2024; further data readouts, product approvals and label extensions anticipated in 20252025 outlook reflects solid revenue growth and positive commercial cash flows to support strategic R&D investments with lower operating cash burn Saint-Herblain (France), March 20, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today reported its consolidated financial results for the y

      3/20/25 2:00:00 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates

       Nine-Month Key Financial Highlights Total revenues of €116.6 million, including product sales of €112.5 millionNet Profit of €24.7 million, including proceeds from the Priority Review Voucher (PRV)1 sale Operating profit of €34.2 million compared to an operating loss of €57.2 million in the first nine-months of 2023 Cash position of €156.3 million Includes €61.2 million in gross proceeds from recent private placement2Lower cash burn expected in the second half of 2024 as cost contributions to the agreed R&D budget for partnered Lyme disease program were completed in the second quarter of the year Full-year 2024 Financial Guidance Narrowed Expected total product sales according to guidan

      11/7/24 1:00:00 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VALN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Valneva SE

      SC 13D/A - Valneva SE (0001836564) (Subject)

      9/20/24 4:00:37 PM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Valneva SE (Amendment)

      SC 13G/A - Valneva SE (0001836564) (Subject)

      2/14/24 8:59:33 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Valneva SE (Amendment)

      SC 13D/A - Valneva SE (0001836564) (Subject)

      6/30/23 9:00:06 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VALN
    Leadership Updates

    Live Leadership Updates

    See more
    • Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board

      Saint-Herblain (France), June 26, 2024 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Board of Directors were approved by the shareholders at its Combined General Meeting (CGM) held today in Lyon, France. Among the adopted resolutions were approval of the 2023 financial statements, delegations for the management board to increase Valneva's share capital and/or issue financial instruments, and the appointment of a new director to its Board. Ms. Danièle Guyot-Caparros was appointed to Valneva's Board of Directors for a three-year term. Ms. Guyot-Caparros has a proven track record in finance and business

      6/26/24 11:45:00 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer

      Saint-Herblain (France), May 21, 2024 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced the appointment of Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer (CSO) and Executive Committee member, effective June 3, 2024. Valneva decided to complement its Executive Team with an accomplished R&D leader to oversee the further evolution of the Company´s R&D portfolio. Specifically, Dr. Schuitemaker will focus on accelerating Valneva's pre-clinical and translational R&D activities in support of the Company's strategic ambition to provide first-, best- or only-in-class vaccine solutions. Dr. Schuitemaker brings more than two decades of experience in vacc

      5/21/24 1:00:00 AM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Valneva Announces Successful Outcome of its AGM and the Appointment of Pfizer's Former Vaccine R&D Head to its Supervisory Board

      Saint-Herblain (France), June 21, 2023 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Management Board were approved by the shareholders at its Annual General Meeting (AGM) held today in Lyon, France. Among the adopted resolutions were approval of the 2022 financial statements, delegations for the management board to increase Valneva's share capital and/or issue financial instruments, as well as the appointment of a new Supervisory Board member and the reappointment of two of them. Dr Kathrin U Jansen, Ph.D., a German national with over 30 years of vaccine R&D experience, was appointed to Valneva's Supervisory

      6/21/23 12:15:00 PM ET
      $VALN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care